Physicians' Academy for Cardiovascular Education

Agenda Topics ▼Video ▼Online-CME News ▼Meeting Reports Slides ▼About

ACC 18 ▼BET Inhibition ▼CV Inflammation ▼Diabetes & CVD ▼Expert Meeting GLP-1, CVD & T2DM ▼Invest in your arteries ▼PCSK9 ▼

HoFH

Feb. 8, 2015

Continue reading:

5 Things a cardiologist should know about diabetes

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

ACC 18

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

The future of renal denervation in the treatment of hypertension

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

ACS

People with ACS and diabetes particularly benefit from PCSK9 inhibitor and statin treatment

News - June 25, 2018

CV risk remains high up to 5 years after TIA or minor stroke

Literature - May 31, 2018 - Amarenco P, et al. - New Engl J Med 2018

Treatment with statin before PCI intervention reduces MACE in patients with ACS

3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil

Atherosclerosis

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands

DPP-4 inhibition may reduce carotid atherosclerosis in T2DM patients in primary prevention

Literature - June 11, 2018 - Tanaka A, et al. - Int J Cardiol 2018

Atrial fibrillation

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK

Nut consumption inversely associated with risk on AF and HF

Literature - July 10, 2018 - Larsson SC, et al. - Heart 2018

GRAND DEBATE | Is catheter ablation superior to drugs in the treatment of patients with AF and HF?

ESC Heart Failure 2018, Vienna

BET Inhibition

LDL-c: Done Deal, Next Epigenetics?

Agenda - Aug. 25, 2018 - ESC 2018, Munich, Germany

First inhibitor of BET transcriptional regulators improves kidney function in CKD patients with CAD

Literature - Apr. 3, 2018 - Kulikowski E, et al. - Kidney Blood Press Res. 2018

Meeting Impression | Managing Diabetes & CVD: Is epigenetics a new way forward?

August 26, 2017 - ESC

CV Inflammation

Mechanisms involved in HFpEF and how they are or may be targeted for therapy

Literature - June 26, 2018 - Lam CSP et al., - Eur Heart J 2018

Yogurt consumption before an unhealthy meal reduces postprandial inflammation

Literature - May 24, 2018 - Pei R, et al. - J Nutr 2018

Cardiovascular Inflammation Reduction Trial (CIRT) stopped early

News - May 22, 2018

CVRM

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden

Diabetes

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - Prof. Faiez Zannad - Paris, France

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland

Phase 3 SGLT2 inhibitor renal outcomes trial stopped early due to positive efficacy findings

News - July 17, 2018

Diabetes & CVD

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - Prof. Faiez Zannad - Paris, France

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland

Phase 3 SGLT2 inhibitor renal outcomes trial stopped early due to positive efficacy findings

News - July 17, 2018

Expert Meeting GLP-1, CVD & T2DM

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

Familial Hypercholesterolemia

Oral microsomal triglyceride transfer protein inhibitor is beneficial in HoFH

Literature - June 28, 2018 - Blom DJ, et al. - Orphanet J Rare Dis 2018

PCSK9 inhibition: Science, Outcomes & Guidance

Agenda - Aug. 25, 2018 - ESC 2018, Munich, Germany

Familial hypercholesterolemia: Diagnosis and management

10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa

GLP-1 RA & CVD

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - Prof. Faiez Zannad - Paris, France

Oral GLP-1 receptor agonist reduces HbA1c and body weight in T2DM patients

News - July 12, 2018

Dual GLP-1 and glucagon receptor agonist improves glycemic control and reduces body weight

Literature - July 4, 2018 - Ambery P et al. - Lancet 2018

Heart Failure

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore

Atrial fibrillation & HFpEF: Novel device and therapeutic approaches

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK

Nut consumption inversely associated with risk on AF and HF

Literature - July 10, 2018 - Larsson SC, et al. - Heart 2018

Hypertension

Even normotensive young blacks have a higher risk of hypertension than whites

Literature - July 19, 2018 - Thomas SJ, et al. - J Am Heart Assoc. 2018

BP response to exercise is exaggerated in hypertensives with controlled resting BP

Literature - June 20, 2018 - Chant B, et al. - Hypertension 2018

Longer exposure to hypertension in mid-life increases risk of dementia

Literature - June 19, 2018 - Abell JG et al. - Eur Heart J 2018

Inflammation Expert Opinions

Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes

5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain

Clinical implications of inhibiting inflammation as risk factor for progression of CVD

5' education - Aug. 27, 2017

Invest in your arteries

Estimating CV risk and treatment benefit

10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands

Importance of hypertension in CVD prevention

10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK

The role of lipids in CVD prevention: Lessons learned about statins

10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands

Lipids

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

Dietary lipids in perspective

10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

Lp(a)

Advancing insights into Lp(a) as a causal factor in CVD

3' education - June 29, 2018 - John Chapman - Paris, France

CVD risk associated with high Lp(a) reduced at low LDL-c in primary prevention setting

Literature - July 5, 2018 - Verbeek R, et al. - Eur Heart J 2018

A large reduction in Lp(a) is necessary to achieve a meaningful reduction of CHD risk

Literature - July 3, 2018 - Burgess S, et al. - JAMA Cardiol 2018

PAH - Q&A

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

What is the underlying pathophysiology of PAH and what are its characteristics?

3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD

Which clinical PH groups can be distinguished?

3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè

PCSK9

A large reduction in Lp(a) is necessary to achieve a meaningful reduction of CHD risk

Literature - July 3, 2018 - Burgess S, et al. - JAMA Cardiol 2018

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK

PCSK9 RNA silencing agent reduces LDL-c in diabetes patients with high CV risk

News - June 27, 2018

PCSK9 expert opinions

PCSK9 inhibition works, but you can’t force biology

10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA

Identification of patients who will benefit is important after FOURIER

10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA

Landmark study with PCSK9 inhibitor will change clinical practice

10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA

Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension: Key answers adressed

Online-CME - This course consists of 3 separate lectures

Why cardiologists should be more interested in PAH

3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA

Novel insights in the management and prognosis of pulmonary hypertension

5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy

Stroke

LDL-triglycerides associated with increased CVD risk

Literature - July 18, 2018 - Saeed A, et al. - JACC 2018

Reduced CV risk with intensive blood pressure treatment in T2DM patients on standard glycemic control

Literature - July 11, 2018 - Tsujimoto T and Kajio H. - Hypertension. 2018

Healthy lifestyle after diabetes diagnosis reduces risk of CVD

Literature - July 3, 2018 - Liu G, et al. - J Am Coll Cardiol

© 2006 - 2018 pace-cme.org - About